- Additionally, GSK will pay Valeant up to $545M based on the achievement of certain regulatory, development and commercialization milestones and the development of additional indications for retigabine. Valeant will co-commercialize with GSK and will share up to 50% of net profits within the US, Canada, Australia, New Zealand and Puerto Rico, and will receive up to a 20% royalty on net sales of retigabine outside those regions.
- The two companies will jointly fund all global research and development expenses for retigabine, and GSK will completely fund the development of VRX698 and the other back-up compounds from the potassium channel opener discovery program. Valeant could receive up to an additional $150M based on the achievement of certain regulatory, development and commercial milestones for VRX698 and the back-up compounds and double-digit royalties on worldwide sales.

Other headlines for [VRX]

• VRX 11/24/2008 08:03am
  Valeant Pharmaceuticals International Reports positive end-of-treatment results with Taribavirin in Phase IIb study- VRX has reported results at end of treatment, week 48 analysis point in the Phase IIb clinical trial for its antiviral more...
  
• VRX 11/14/2008 08:03am
  Valeant Pharmaceuticals International Acquires DermaTech for AU$19M- Acquired DermaTech Pty Ltd, an Australian specialty pharmaceutical company focused on dermatology products marketed throughout Australia and overseas - This more...
  
• VRX 11/6/2008 08:01am
  Valeant Pharmaceuticals International Reports Q3 -$0.11 v $0.17e, R $168.4M v $209.9Me- Q3 gross margin 66% v 65% y/y
  
• VRX 10/28/2008 08:16am
  Valeant Pharmaceuticals International Brean Murray Initiates VRX with Sell, price target: $9
  
• VRX 10/24/2008 08:00am
  Valeant Pharmaceuticals International Announces Promotion Agreement for Diastat AcuDial, financial terms not disclosed- Under the terms of the agreement, GSK will exclusively promote Diastat and Diastat AcuDial to U.S. physicians in more...
  

Healthcare sector headlines

• MYL Today 07:30am
  Mylan Laboratories Inc Announces settlement agreement with Novartis related to Femara First-to-File Opportunity- Under the agreement, Mylan is provided a patent license that will enable the company to market Letrozole more...
  
• XNPT Today 07:30am
  XenoPort Inc Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroesophageal Reflux Disease- The primary analysis comparing XP19986 to placebo did not reach more...
  
• TGEN Today 07:30am
  Targeted Genetics Corp Realigns product development priorities; Implements cost reduction measures- To focus on its ocular and neurological product candidates and its first use of expressed RNAi - Company has reduced its more...
  
• XNPT Today 07:27am
  XenoPort Inc Halted: News pending
  
• SVA Today 07:04am
  Sinovac Biotech Releases statement on Sinovac vaccine suspension- Health Services Bureau of Fengtai District in the City of Beijing suspended the use of 83 doses of inactivated hepatitis A vaccine Healive(R), more...